XORTX Therapeutics Inc.
XRTX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 495.10K | 393.00K | 476.00K | 488.80K | 420.60K |
| Depreciation & Amortization | 29.10K | 29.40K | 27.60K | 26.00K | 26.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 579.10K | 479.40K | 690.40K | 791.00K | 454.50K |
| Operating Income | -579.10K | -479.40K | -690.40K | -791.00K | -454.50K |
| Income Before Tax | -590.50K | -649.50K | -717.70K | -698.70K | 122.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -590.50K | -649.50K | -717.70K | -698.70K | 122.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -590.50K | -649.50K | -717.70K | -698.70K | 122.50K |
| EBIT | -579.10K | -479.40K | -690.40K | -791.00K | -454.50K |
| EBITDA | -572.00K | -472.00K | -681.80K | -782.70K | -446.00K |
| EPS Basic | -0.45 | -0.67 | -0.95 | -0.93 | 0.19 |
| Normalized Basic EPS | -0.28 | -0.42 | -0.59 | -0.58 | 0.12 |
| EPS Diluted | -0.45 | -0.67 | -0.95 | -0.95 | 0.19 |
| Normalized Diluted EPS | -0.28 | -0.42 | -0.59 | -0.58 | 0.12 |
| Average Basic Shares Outstanding | 1.31M | 971.30K | 757.60K | 747.40K | 655.20K |
| Average Diluted Shares Outstanding | 1.31M | 971.30K | 757.60K | 747.40K | 655.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |